Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study
Obesity · 2025
DOI: 10.1002/oby.24290 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Obesity, 2025. Verfasst von Lee M Kaplan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA. Hauptthemen laut MEDLINE: Obesity, Anti-Obesity Agents, Health Personnel. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objective
The objective of this study was to understand the perceptions of and drivers/barriers to antiobesity medication (AOM) use among people with obesity (PwO) and health care providers (HCPs) in the United States.
Methods
In 2022, PwO and HCPs completed cross‐sectional surveys that included questions on perceptions of obesity management and AOMs. Data were analyzed using descriptive statistics.
Results
Survey participants (1007 PwO and 474 HCPs) emphasized the effectiveness of lifestyle change and the patient's responsibility to address obesity. PwO reported a willingness to take newly approved AOMs long term. HCPs believed that their patients would adhere to AOMs long term if they experienced success. Both PwO and HCPs perceived an increased effectiveness of a multimodal approach to combining AOMs with HCP‐guided lifestyle intervention. Potential barriers to long‐term use of AOMs for both groups included concerns regarding long‐term side effects and outcomes, costs and insurance coverage, and perception of AOMs that do not align with treatment of a chronic disease.
Conclusions
PwO and HCPs are interested in new AOM options, but educational gaps remain as a barrier to recommended multimodal chronic care. Ongoing education that includes the known effectiveness and safety data of newer AOMs and pending outcome trials could improve shared decision‐making in obesity care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
- Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
- Weill Cornell Medical College, New York, New York, USA.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Oracle Life Sciences, Austin, Texas, USA.
ORCID-Profile: Lee M Kaplan, Kimberly Gudzune, Jamy Ard, Julia P Dunn
Förderung
- Eli Lilly and Company
Zitieren
APA
Kaplan, L. M., Gudzune, K., Ard, J., Kumar, R., Ahmad, N. N., Kan, H., Sims, T. J., Poon, J. L., King-Concialdi, K., Beusterien, K., Drakeley, S., Dunn, J. P., Kahan, S., & OBSERVE Study (2025). Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study. Obesity. https://doi.org/10.1002/oby.24290
Vancouver
Kaplan LM, Gudzune K, Ard J, Kumar R, Ahmad NN, Kan H, et al. Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study. Obesity. 2025. doi:10.1002/oby.24290
BibTeX
@article{Kaplan2025,
author = {Kaplan, Lee M and Gudzune, Kimberly and Ard, Jamy and Kumar, Rekha and Ahmad, Nadia N and Kan, Hong and Sims, Tracy J and Poon, Jiat Ling and King-Concialdi, Kristen and Beusterien, Kathleen and Drakeley, Sheila and Dunn, Julia P and Kahan, Scott and OBSERVE Study, OBSERVE Study},
title = {Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.24290}
}
EUVIMED